NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $390M | $1.5B | $1.1B | $1.0B | $989M | $711M | $801M | $671M | $651M | $516M | $307M | $379M | $194M | $146M | $173M | $129M | $127M | $37M |
| Inventory | $104M | $69M | $57M | $38M | $35M | $31M | $28M | $17M | $11M | $1.0M | $0 | — | — | — | — | — | — | — |
| Current assets | $1.6B | $2.5B | $1.7B | $1.6B | $1.5B | $973M | $1.0B | $831M | $738M | $555M | $310M | $384M | $198M | $148M | $189M | $132M | $133M | — |
| Goodwill | $501M | $6.1M | $5.7M | $5.8M | $5.4M | $0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Intangible assets | $2.2B | $4.7M | $37M | $36M | $37M | $0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | $5.4B | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B | $1.7B | $1.3B | $993M | $818M | $365M | $475M | $243M | $155M | $196M | $138M | $144M | — |
| Current liabilities | $875M | $743M | $508M | $655M | $538M | $246M | $187M | $565M | $88M | $54M | $30M | $26M | $16M | $12M | $16M | $47M | $53M | — |
| Total liabilities | $1.7B | $1.4B | $1.1B | $1.0B | $661M | $699M | $609M | $669M | $512M | $445M | $50M | $50M | $34M | $34M | $42M | $78M | $125M | — |
| Shareholders' equity | $3.7B | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B | $1.1B | $637M | $481M | $372M | $315M | $424M | $209M | $120M | $154M | $60M | $19M | $4.0M |
| Shares outstanding | 101.6M | 100.4M | 99.7M | 99.5M | 96.6M | 95.2M | 93.9M | 92.3M | 90.8M | 89.3M | 87.1M | 86.5M | 77.2M | 67.8M | 66.5M | 66.2M | — | — |
| Current ratio | 1.87 | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 | 1.47 | 8.36 | 10.20 | 10.21 | 14.94 | 12.65 | 12.69 | 12.10 | 2.81 | 2.52 | — |